Caspase-1 Activity As a Possible Predictor of Apoptosis Induced by Cisplatin in Gastric Cancer Cells
Overview
Affiliations
Recent studies have shown that caspases, which are cystein proteases, elevate endonuclease activity and induce apoptosis. Caspase-1, an interleukin-1beta converting enzyme, has been reported to be related with anti-cancer drug induced apoptosis as well as with caspase-3. To elucidate the caspase-1 activity, which might be a predictor for the effect of chemotherapy, we examined the changes of caspase-1 activity induced after exposure to cisplatin (CDDP) in six gastric cancer cell lines. A high correlation between the 50% inhibitory concentration (IC50) and caspase-1 activity ratio was shown (r=0.83, p=0.041) (caspase-1 activity ratio: the caspase-1 activity of cells at 4 h after CDDP treatment/the caspase-1 activity of untreated cells). Further, we examined the correlation between caspase-1 activity and apoptosis induced by CDDP in two cell lines that have very different CDDP sensitivities; OCUM-2M and OCUM-2M/DDP (IC50; 0. 85+/-0.4 microg/ml and 9.0+/-1.2 microg/ml, respectively). The apoptotic index of OCUM-2M was significantly higher than that of OCUM-2M/DDP (19.8+/-3.8% vs. 4.5+/-1.2%, respectively; p=0.0005). In both cell lines, caspase-1 activity began to increase immediately after exposure to CDDP and peaked at approximately 4 h after cessation of exposure to CDDP, and gradually decreased thereafter. The caspase-1 activity of OCUM-2M was approximately 1.8-times higher than that of OCUM-2M/DDP at 4 h after exposure to CDDP. Taken together, our results indicate that evaluating the changes of caspase-1 activity after exposure to CDDP may be useful to predict apoptosis following CDDP treatment in gastric cancer cells.
Bjorkblom B, Jonsson P, Tabatabaei P, Bergstrom P, Johansson M, Asklund T Br J Cancer. 2019; 122(2):221-232.
PMID: 31819184 PMC: 7052137. DOI: 10.1038/s41416-019-0652-x.
Qian J, Qu H, Yang L, Yin M, Wang Q, Gu S Oncologist. 2012; 17(12):1551-61.
PMID: 22843554 PMC: 3528388. DOI: 10.1634/theoncologist.2011-0419.
Husain Z, Holodick N, Day C, Szymanski I, Alper C J Clin Immunol. 2006; 26(2):113-25.
PMID: 16758339 DOI: 10.1007/s10875-006-9001-y.